Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in Advanced CTCL
NCT01098656Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2010
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS) comparing Observation with Lenalidomide (2 arms). Primary endpoint: Progression-free survival. Started Jul 2010; status: terminated.
02
Drugs
lenalidomide
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT01098656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01098656.